

**Supplementary Table 1.** Subgroup analyses for the concurrent achievement of continuous glucose monitoring-based targets<sup>a</sup> in the multivariate logistic regression analysis<sup>b</sup>

	No. of event/total	Age, yr	Male sex	BMI, kg/m <sup>2</sup>	Glycosylated hemoglobin, % <sup>c</sup>	Duration of Diabetes, yr	PCGR2 <sup>d</sup>	Daily sleep duration, min <sup>e</sup>	Daytime step counts <sup>d</sup>	Calorie intake, kcal/day <sup>f</sup>
Total	37/122	0.98 (0.93-1.04)	0.21 (0.07-0.66)	0.94 (0.84-1.06)	0.93 (0.89-0.98)	0.96 (0.89-1.03)	1.11 (1.02-1.22)	1.00 (0.92-1.08)	1.15 (1.03-1.28)	1.04 (0.92-1.17)
Glycosylated hemoglobin, %										
<7.8	26/61	0.97 (0.91-1.04)	0.12 (0.03-0.59)	0.92 (0.78-1.08)	0.89 (0.78-1.01)	0.95 (0.87-1.04)	1.05 (0.93-1.20)	1.01 (0.91-1.11)	1.19 (1.01-1.39)	1.04 (0.90-1.22)
≥7.8	11/61	1.03 (0.91-1.17)	0.31 (0.04-2.55)	0.95 (0.73-1.25)	0.90 (0.79-1.02)	0.94 (0.81-1.09)	1.19 (1.01-1.42)	0.94 (0.80-1.11)	1.10 (0.95-1.28)	1.11 (0.85-1.45)
<i>P</i> for interaction		0.753	0.286	0.530	0.759	0.961	0.111	0.415	0.632	0.338
eGFR, mL/min/1.73 m <sup>2</sup>										
<90	12/46	1.25 (0.91-1.73)	0.001 (0.00004-1.54)	1.21 (0.68-2.16)	0.71 (0.52-0.99)	0.72 (0.51-1.01)	1.78 (1.04-3.05)	0.74 (0.49-1.12)	1.83 (1.03-3.25)	0.91 (0.58-1.44)
≥90	25/76	0.97 (0.91-1.04)	0.26 (0.07-0.98)	0.95 (0.83-1.08)	0.96 (0.90-1.02)	0.99 (0.90-1.08)	1.09 (0.97-1.23)	1.01 (0.93-1.11)	1.11 (0.98-1.26)	1.04 (0.91-1.19)
<i>P</i> for interaction		0.899	0.484	0.856	0.177	0.297	0.229	0.504	0.892	0.490
Urine ACR, mg/g										
<30	29/66	1.01 (0.94-1.08)	0.18 (0.04-0.75)	0.93 (0.80-1.07)	0.97 (0.91-1.03)	1.00 (0.91-1.10)	1.14 (1.02-1.28)	1.01 (0.92-1.11)	1.06 (0.94-1.19)	1.05 (0.90-1.21)
≥30	8/56	0.76 (0.56-1.01)	0.05 (0.0004-6.63)	0.84 (0.47-1.49)	0.81 (0.62-1.06)	0.86 (0.64-1.15)	1.10 (0.79-1.53)	0.90 (0.61-1.35)	2.03 (1.08-3.82)	1.04 (0.66-1.62)
<i>P</i> for interaction		0.032	0.669	0.820	0.232	0.117	0.836	0.608	0.171	0.738
Frequency of prandial insulin										
0, 1	22/64	0.92 (0.83-1.02)	0.18 (0.04-0.83)	0.93 (0.76-1.14)	0.93 (0.87-1.01)	0.99 (0.90-1.08)	1.07 (0.93-1.24)	0.94 (0.84-1.06)	1.18 (1.01-1.38)	0.94 (0.78-1.14)
2, 3	15/58	1.04 (0.95-1.14)	0.17 (0.02-1.28)	0.95 (0.79-1.14)	0.93 (0.87-1.00)	0.91 (0.81-1.02)	1.06 (0.92-1.22)	1.08 (0.93-1.26)	1.17 (0.99-1.38)	1.16 (0.94-1.42)
<i>P</i> for interaction		0.209	0.256	0.604	0.701	0.843	0.957	0.268	0.434	0.270
DPP-4 inhibitor										
No	22/65	0.94 (0.86-1.03)	0.37 (0.07-1.95)	0.99 (0.83-1.20)	0.90 (0.82-0.99)	1.00 (0.93-1.07)	1.18 (1.03-1.35)	0.99 (0.88-1.10)	1.19 (0.98-1.45)	0.97 (0.81-1.16)
Yes	15/57	1.00 (0.91-1.10)	0.15 (0.02-0.97)	0.71 (0.49-1.03)	0.95 (0.88-1.02)	0.88 (0.77-1.02)	1.07 (0.90-1.26)	0.96 (0.81-1.14)	1.22 (0.99-1.52)	1.14 (0.90-1.44)
<i>P</i> for interaction		0.293	0.822	0.039	0.432	0.538	0.128	0.933	0.650	0.686

BMI, body mass index; PCGR2, 2-hour postprandial C-peptide-to-glucose ratio; eGFR, estimated glomerular filtration rate; ACR, albumin to creatinine ratio; DPP-4, dipeptidyl peptidase 4.

<sup>a</sup>Time in range (TIR)<sup>70-180</sup> >70%, time above range (TAR)<sup>>180</sup> <25%, time below range (TBR)<sup><70</sup> <4%, TBR<sup><54</sup> <1%, and coefficient of variation ≤36%. <sup>b</sup>Each variable was adjusted for the other variables in the table. <sup>c</sup>Per 0.1 of glycosylated hemoglobin. <sup>d</sup>Per 0.1 of LnPCGR2 and Ln (daytime step counts/100). <sup>e</sup>Per 10 minutes of daily sleep duration. <sup>f</sup>Per 100 kcal of daily calorie intake.